Thus, anti-IgE monoclonal antibodies (e.g., omalizumab and ligelizumab), that inhibit mast cell degranulation, have been developed and approved by the Food and Drug Administration for the treatment of asthma and CSU. The gene discussed is IGHE; the disease is asthma.